NEUROBIS Phase II Trial Launches to Evaluate Cannabis-Based Medicine for Neurodegenerative Diseases
核心洞察
The NEUROBIS study, a 36-month phase II randomized, double-blind, placebo-controlled clinical trial, has enrolled its first patient to evaluate cannabis-based medicines (搜索) in 180 patients with ALS, Parkinson's disease (搜索), or Alzheimer's disease (搜索).
The trial is authorized and funded by the Italian Ministry of Health (搜索) and aims to assess the efficacy and safety of full-spectrum cannabis extract (搜索) for improving quality of life in neurodegenerative diseases (搜索).
Professor Letizia Mazzini, director of the ALS Center in Novara (搜索) and internationally renowned neurologist with over 30 years of experience, leads the clinical trial in collaboration with Avextra (搜索).
A groundbreaking phase II clinical trial investigating cannabis-based medicines (搜索) for neurodegenerative diseases (搜索) has enrolled its first patient in Italy, marking a significant milestone in exploring alternative therapeutic approaches for conditions with limited treatment options. The NEUROBIS study represents the first randomized, double-blind, placebo-controlled trial of its kind to systematically evaluate cannabis-based medicines in patients with amyotrophic lateral sclerosis (搜索) (ALS), Parkinson's disease (搜索), and Alzheimer's disease (搜索).
Trial Design and Scope
The 36-month clinical trial has received authorization and funding from the Italian Ministry of Health (搜索) through the Ricerca Finalizzata 2022 program. The study will enroll 180 patients across three major neurodegenerative conditions, evaluating the efficacy of cannabis-based medicines (搜索) in terms of quality of life improvements and safety profiles.
The trial focuses on full-spectrum cannabis extract (搜索), which researchers believe may have potential to modulate neurophysiological systems involved in degenerative processes. This approach represents a departure from traditional single-compound studies, instead examining the therapeutic potential of the complete cannabinoid profile.
Clinical Leadership and Expertise
Professor Letizia Mazzini, an internationally renowned neurologist with over 30 years of experience in neurodegenerative disease research, leads the clinical trial. As director of the ALS Center in Novara (搜索) and one of Italy's leading experts on motor neuron diseases, Professor Mazzini brings extensive clinical expertise to the study.
"We are proud to launch this pioneering clinical trial in Italy," states Professor Mazzini. "Thanks to our collaboration with Avextra (搜索), we are combining clinical expertise and innovation to rigorously explore the therapeutic potential of medical cannabis as an additional option for patients suffering from neurodegenerative diseases (搜索). Our goal is to generate high-quality scientific data that can translate into real clinical benefits."
Addressing Unmet Medical Needs
The trial addresses a critical gap in treatment options for neurodegenerative diseases (搜索), which represent one of the biggest challenges of our time. In Germany alone, approximately 1.8 million people currently live with dementia (搜索), with projections indicating this number will rise to 2.7 million by 2050. The increasing prevalence, combined with longer life expectancy, places growing pressure on patients, families, and healthcare systems.
Despite advances in research, current treatment options remain inadequate in providing effective symptomatic relief and sustainable improvements in patients' quality of life. This clinical reality underscores the urgent need for additional therapeutic options supported by robust clinical evidence.
Research Collaboration
The NEUROBIS study represents a collaboration between academic clinical expertise and industry innovation through the partnership with Avextra (搜索). This collaboration aims to generate high-quality scientific data that could potentially translate into meaningful clinical benefits for patients with neurodegenerative diseases (搜索).
The study's rigorous design, including its randomized, double-blind, placebo-controlled methodology, reflects the commitment to producing reliable evidence that could inform future treatment guidelines and regulatory decisions for cannabis-based medicines (搜索) in neurodegenerative conditions.